Corvidia Therapeutics Secures $60 Million in Series B Funding to Accelerate Clinical Work
Corvidia Therapeutics Inc., a leading clinical stage biotechnology company, today announced the close of a $60 million USD Series B funding round. The financing will accelerate growth of Corvidia’s ongoing clinical programs, expand scientific and market access capabilities and explore new treatment areas.
Venrock led the Series B financing and was joined by five additional new investors: Andera (formerly Edmond de Rothschild), Cormorant Asset Management, HBM Healthcare Investments, Fresenius Medical Care Ventures GmbH and Venrock Healthcare Capital Partners (VHCP). Series A investors Apple Tree Partners, MedImmune, the global biologics Research and Development arm of AstraZeneca, and Sofinnova Partners, the founding seed investor, also participated in this round.
“We are extremely pleased to have reached such an important milestone in Corvidia’s advancement as a biotechnology company,” said Marc de Garidel, Chief Executive Officer of Corvidia Therapeutics Inc. “This funding is critical to accelerating our clinical programs and adding the necessary scientific and market access infrastructure which will drive our growth in developing precision therapies for patients across a range of complex diseases.” Mr. de Garidel, former Chairman and Chief Executive Officer of Ipsen SA, joined Corvidia in March 2018.
Corvidia Therapeutics is nearing completion of a Phase 2 clinical trial for a genetically-defined patient population living with advanced chronic kidney disease. Presently, the Company is scientifically-focused on cardiovascular indications utilizing the study of genetic variations to ultimately deliver precise treatments to specific patients who have an unmet medical need. The Series B funding will be used to progress the lead clinical programs in chronic kidney disease and beyond as well as advance pre-clinical programs. The Company will add new talent to support these advancing programs.
“Corvidia’s innovative approach to cardiovascular drug development allows them to parse complex, heterogeneous conditions and validate disease pathways in patient subpopulations before beginning clinical trials,” says Karim Helmy MD, PhD, Vice President, Venrock. “We have confidence that Corvidia’s highly-respected and experienced team will continue to identify critical therapeutic targets for these devastating diseases through their pioneering approach.”
Several changes to Corvidia’s executive management team were announced in concert with the closing of Series B funding. Four of the founding executive team members have been named to new positions: Rahul Kakkar MD is Chief Medical Officer and Chief Strategy Officer; Matt Devalaraja, DVM, PhD is Executive Vice President and Head of Research and Development; Ram Aiyar, PhD, MBA is Executive Vice President and Head of Business Development. Corvidia’s former chief executive officer, Michael Davidson MD, was named Chief Science Officer upon the appointment of Mr. de Garidel as CEO.
About Corvidia Therapeutics Inc.
Corvidia Therapeutics Inc. is a clinical stage biotechnology company based in Waltham, Massachusetts pioneering the next generation of cardiovascular and cardio-renal therapies. Corvidia’s pipeline programs utilize functional genomics to precisely identify patients with unique sensitivity to specific biologic pathways, allowing for rapid development and an accelerated path-to-market for drugs targeting those pathways. Among our portfolio of novel therapeutic candidates, we presently have an experimental therapy in Phase 2 development for a genetically-defined patient population with chronic kidney disease. Corvidia’s other preclinical programs are in various stages of development and are focused on cardiovascular diseases. For more information, please visit www.corvidiatx.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180425005032/en/
Contact information
Press Inquiries:
McDougall Communications on behalf of
Corvidia Therapeutics Inc.
Elizabeth Harness, +1 (585) 435 -7379
elizabeth@mcdougallpr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Diagnostics.ai Launches Industry's First CE-IVDR Certified Transparent AI Platform for Molecular Diagnostics as Regulatory Deadlines take Effect29.5.2025 09:13:00 EEST | Press release
Revolutionary Platform Sets New Benchmark for Transparency and Compliance in Diagnostic AI As the May 26th CE-IVDR compliance deadline comes into effect, Diagnostics.ai launches the industry’s first fully-transparent machine learning platform for clinical real-time PCR diagnostics – demonstrating exactly how each result was achieved, a first for molecular-testing machine learning. The technology is backed by over 15 years of experience and millions of successfully processed samples with >99.9% proven accuracy. The CE-IVDR Strategic Advantage Platform is Diagnostics.ai's response to the new wave of stringent EU regulations under the In Vitro Diagnostic Medical Devices Regulation (IVDR), which demand heightened standards for diagnostic accuracy, reproducibility, and algorithm transparency. “While most diagnostic algorithms remain an impenetrable ‘black box,’ the PCR.AI API was engineered with transparency included from the ground up,” said Aron Cohen, Chief Executive Officer of Diagnosti
From Ancient Grounds to an Intelligent Future: The 1st International Humanoid Olympiad Launches in Olympia, Greece29.5.2025 01:47:00 EEST | Press release
This year, Olympia, Greece, the birthplace of the Olympic Games, welcomes the inaugural International Humanoid Olympiad. From August 29th to September 2nd, at the International Olympic Academy in Olympia, humanoid robots will participate in demonstrations and Olympic-inspired games, showcasing their dexterity and intelligence, while global leaders in robotics and AI will share insights through expert talks and workshops. Blending millennia-old values, ethos, and ideals with a bold vision for the future, the event will spotlight how human creativity and robotics are shaping the future. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250528788233/en/ This global gathering brings together state-of-the-art humanoid robots in spectacular showcases designed to captivate audiences of all ages and backgrounds while their creators, researchers, engineers, students, and visionaries are pushing the boundaries of what intelligent machine
Mary Kay Inc. Awards 10 Grants to Young Innovators at 2025 Regeneron International Science and Engineering Fair28.5.2025 23:29:00 EEST | Press release
Mary Kay Inc., a global advocate for furthering young women’s education and encouraging youth to follow their STEM dreams, returned for a second year as a Special Awards Organization at the Regeneron International Science and Engineering Fair (Regeneron ISEF) in Columbus, Ohio. Ten grants totaling nearly $10,000 were awarded to standout high school-aged students excelling in innovative projects spanning topics from finding cures for cancers affecting women to sustainable packaging innovation and protecting our planet’s most valuable resources. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250528325390/en/ Kristin Dasaro, Director, Package Engineering and Sustainability at Mary Kay, greets Brazilian cancer researcher, Carolina de Araujo Pereira da Silva, who received back-to-back awards from Mary Kay for innovative findings in the malignancy of tumors. (Photo Credit: Mary Kay Inc.) Each year, the event convenes nearly 2,000
Duravant Completes Acquisition of Pattyn28.5.2025 20:44:00 EEST | Press release
Duravant LLC (“Duravant”), a global engineered equipment and automation solutions provider to the protein processing, food sorting and handling, packaging, and material handling sectors, announced the completion of its acquisition of the Pattyn Group BV (“Pattyn”), a leading manufacturer of packaging automation systems headquartered in Bruges, Belgium. The transaction was first announced on February 7, 2025, and was completed today. With over 70 years of expertise, Pattyn is a trusted partner for companies looking to automate bulk packaging operations in industries ranging from food and ingredients to non-food applications. Pattyn has been a world-renowned brand specializing in bag-in-box packaging technology, and their comprehensive end-of-line solutions span the entire packaging process from case erecting and bag inserting to weigh filling, bag and case closing, and palletizing. “We are extremely excited to welcome Pattyn to the Duravant family,” said Mike Kachmer, Chairman and CEO o
Rimini Street Appoints Vijay Kumar as EVP and Chief Operating Officer28.5.2025 19:00:00 EEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, management and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced the appointment of Vijay Kumar as executive vice president (EVP) and chief operating officer (COO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250528704180/en/ Rimini Street Appoints Vijay Kumar as EVP and Chief Operating Officer In this role, Mr. Kumar leads product management, service strategy and offerings for Rimini Street’s “Support, Optimize and Innovate” solutions and oversees Rimini Street’s Global Capability Centers (GCC). Mr. Kumar also drives operational efficiency and innovation of the portfolio to increase profitability and accelerate top line revenue growth. New COO Brings Broad Operational Experience and Capabilities Kumar is a seasoned technology executive with more than 25 yea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom